Prostate cancer is known to be caused by the androgen receptor (AR) axis and testosterone, emerging evidence highlights the significance of epigenetic modifications in mediating androgen-dependent tumorigenesis and therapy resistance.
Methodology
The literature search was conducted in Scopus, PubMed, and Google Scholar following PRISMA guidelines. Case-control, clinical and preclinical studies, and human clinical trials analyzed epigenetic modifications in testosterone-mediated prostate cancer were included. Studies that did not analyze epigenetic alterations in prostate cancer or focused on other cancer types were excluded.
Result
Prostate cancer is largely caused by DNA methylation, which controls gene expression. Genes are silenced when CpG islands are hypermethylated, and genomic instability is exacerbated by hypomethylation. Emerging therapeutic strategies, such as DNMT inhibitors and combination therapies with AR pathway inhibitors, are being explored to target aberrant DNA methylation in prostate cancer treatment. Prostate cancer development and androgen receptor signaling are influenced by chromatin remodeling and gene regulation, both of which are significantly impacted by histone changes.
Conclusion
Epigenetic dysregulation drives prostate cancer progression by silencing tumor suppressors, activating oncogenes, and promoting therapy resistance. These changes have potential as therapeutic targets for better patient clinical care.
SiegelRLMillerKDFuchsHE, et al.Cancer statistics, 2021. CA Cancer J Clin2021; 71(1): 7–33.
2.
RebbeckTR. Prostate cancer genetics: variation by race, ethnicity, and geography. Semin Radiat Oncol2017; 27(1): 3–10.
3.
BoutrosPCFraserMHardingNJ, et al.Spatial genomic heterogeneity within localized, multifocal prostate cancer. Nat Genet2015; 47(7): 736–745.
4.
Van der SteenTTindallDJHuangH. Posttranslational modification of the androgen receptor in prostate cancer. Int J Mol Sci2013; 14(7): 14833–14859.
5.
MassonSBahlA. Metastatic castrate-resistant prostate cancer: dawn of a new age of management. BJU Int2012; 110(8): 1110–1114.
6.
AbeshouseAAhnJAkbaniR, et al.The molecular taxonomy of primary prostate cancer. Cell2015; 163(4): 1011–1025.
7.
RagaviRMuthukumaranPNandagopalS, et al.Epigenetics regulation of prostate cancer: biomarker and therapeutic potential. Urol Oncol2023; 41(8): 340–353.
8.
OkanoMBellDWHaberDA, et al.DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell1999; 99(3): 247–257.
9.
GravinaGLRanieriGMuziP, et al.Increased levels of DNA methyltransferases are associated with the tumorigenic capacity of prostate cancer cells. Oncol Rep2013; 29(3): 1189–1195.
10.
YuYPDingYChenR, et al.Whole-genome methylation sequencing reveals distinct impact of differential methylations on gene transcription in prostate cancer. Am J Pathol2013; 183(6): 1960–1970.
11.
NakayamaTWatanabeMSuzukiH, et al.Epigenetic regulation of androgen receptor gene expression in human prostate cancers. Lab Invest2000; 80(12): 1789–1796.
12.
YoonHYKimSKKimYW, et al.Combined hypermethylation of APC and GSTP1 as a molecular marker for prostate cancer: quantitative pyrosequencing analysis. J Biomol Screen2012; 17(7): 987–992.
13.
MaruyamaRToyookaSToyookaKO, et al.Aberrant promoter methylation profile of prostate cancers and its relationship to clinicopathological features. Clin Cancer Res2002; 8(2): 514–519.
14.
SugiuraMSatoHKanesakaM, et al.Epigenetic modifications in prostate cancer. Int J Urol2021; 28(2): 140–149.
15.
ChoNYKimJHMoonKC, et al.Genomic hypomethylation and CpG island hypermethylation in prostatic intraepithelial neoplasm. Virchows Arch2009; 454(1): 17–23.
16.
FottnerCApostolidisLKrugS, et al.Activity and safety of avelumab in high-grade neuroendocrine tumors and poorly differentiated neuroendocrine carcinomas progressive after chemotherapy (AveNEC trial). Clin Cancer Res2025; 31: OF1–OF867.
17.
BastianPJEllingerJHeukampLC, et al.Prognostic value of CpG island hypermethylation at PTGS2, RAR-beta, EDNRB, and other gene loci in patients undergoing radical prostatectomy. Eur Urol2007; 51(3): 665–674.
18.
EnokidaHShiinaHIgawaM, et al.CpG hypermethylation of MDR1 gene contributes to the pathogenesis and progression of human prostate cancer. Cancer Res2004; 64(17): 5956–5962.
19.
BastianPJYegnasubramanianSPalapattuGS, et al.Molecular biomarker in prostate cancer: the role of CpG Island Hypermethylation. Eur Urol2004; 46(6): 698–708.
20.
ChinSPDickinsonJLHollowayAF. Epigenetic regulation of prostate cancer. Clin Epigenet2011; 2: 151–169.
21.
MajumdarSBucklesEEstradaJ, et al.Aberrant DNA methylation and prostate cancer. Curr Genom2011; 12(7): 486–505.
22.
SchulzWAEloJPFlorlAR, et al.Genomewide DNA hypomethylation is associated with alterations on chromosome 8 in prostate carcinoma. Genes Chromos Cancer2002; 35(1): 58–65.
23.
KouzaridesT. Chromatin modifications and their function. Cell2007; 128(4): 693–705.
24.
EllingerJKahlPVon Der GathenJ, et al.Global levels of histone modifications predict prostate cancer recurrence. Prostate2010; 70(1): 61–69.
25.
Van ReeJHJeganathanKBMalureanuL, et al.Overexpression of the E2 ubiquitin–conjugating enzyme UbcH10 causes chromosome missegregation and tumor formation. J Cell Biol2010; 188(1): 83–100.
26.
KeXSQuYRostadK, et al.Genome-wide profiling of histone h3 lysine 4 and lysine 27 trimethylation reveals an epigenetic signature in prostate carcinogenesis. PLoS One2009; 4(3): e4687.
27.
PomerantzMMQiuXZhuY, et al.Prostate cancer reactivates developmental epigenomic programs during metastatic progression. Nat Genet2020; 52(8): 790–799.
28.
ConteducaVHessJYamadaY, et al.Epigenetics in prostate cancer: clinical implications. Transl Androl Urol2021; 10(7): 3104–3116.
29.
WillardSSKoochekpourS. Regulators of gene expression as biomarkers for prostate cancer. Am J Cancer Res2012; 2(6): 620–657.
30.
El KharrazSDuboisVvan RoyenME, et al.The androgen receptor depends on ligand‐binding domain dimerization for transcriptional activation. EMBO Rep2021; 22(12): e52764.
BoltonECSoAYChaivorapolC, et al.Cell-and gene-specific regulation of primary target genes by the androgen receptor. Genes Dev2007; 21(16): 2005–2017.
33.
WangQCarrollJSBrownM. Spatial and temporal recruitment of androgen receptor and its coactivators involves chromosomal looping and polymerase tracking. Mol Cell2005; 19(5): 631–642.
34.
LinJHaffnerMCZhangY, et al.Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate2011; 71(4): 333–343.
35.
SingalRRamachandranKGordianE, et al.Phase I/II study of azacitidine, docetaxel, and prednisone in patients with metastatic castration-resistant prostate cancer previously treated with docetaxel-based therapy. Clin Genitourin Cancer2015; 13(1): 22–31.
36.
KaushikDVashisthaVIsharwalS, et al.Histone deacetylase inhibitors in castration-resistant prostate cancer: molecular mechanism of action and recent clinical trials. Ther Adv Urol2015; 7(6): 388–395.
37.
FerrariACAlumkalJJSteinMN, et al.Epigenetic therapy with panobinostat combined with bicalutamide rechallenge in castration-resistant prostate cancer. Clin Cancer Res2019; 25(1): 52–63.
38.
PeggNWorthingtonJYoungB, et al.Novel small molecule inhibitors of p300/CBP down-regulate androgen receptor (AR) and c-Myc for the treatment of prostate cancer and beyond. Cancer Res2018; 78: 3991.
